Literature DB >> 31883763

Synthesis and labeling of a squaric acid containing PSMA-inhibitor coupled to AAZTA5 for versatile labeling with 44Sc, 64Cu, 68Ga and 177Lu.

Lukas Greifenstein1, Tilmann Grus1, Johannes Nagel1, Jean Phillip Sinnes1, Frank Rösch2.   

Abstract

Entities:  

Keywords:  (177)Lu; (44)Sc; (64)Cu; (68)Ga; AAZTA; DATA; PSMA

Year:  2019        PMID： 31883763     DOI： 10.1016/j.apradiso.2019.108867

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN： 0969-8043            Impact factor:   1.513


× No keyword cloud information.
  7 in total

Review 1.  A review of advances in the last decade on targeted cancer therapy using 177Lu: focusing on 177Lu produced by the direct neutron activation route.

Authors:  Rubel Chakravarty; Sudipta Chakraborty
Journal:  Am J Nucl Med Mol Imaging       Date:  2021-12-15

2.  Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators.

Authors:  Euy Sung Moon; Filipe Elvas; Gwendolyn Vliegen; Stef De Lombaerde; Christel Vangestel; Sven De Bruycker; An Bracke; Elisabeth Eppard; Lukas Greifenstein; Benedikt Klasen; Vasko Kramer; Steven Staelens; Ingrid De Meester; Pieter Van der Veken; Frank Rösch
Journal:  EJNMMI Radiopharm Chem       Date:  2020-07-29

Review 3.  Cold Kit Labeling: The Future of 68Ga Radiopharmaceuticals?

Authors:  Nicolas Lepareur
Journal:  Front Med (Lausanne)       Date:  2022-02-10

4.  Hybrid Chelator-Based PSMA Radiopharmaceuticals: Translational Approach.

Authors:  Hanane Lahnif; Tilmann Grus; Stefanie Pektor; Lukas Greifenstein; Mathias Schreckenberger; Frank Rösch
Journal:  Molecules       Date:  2021-10-20       Impact factor: 4.411

Review 5.  AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications.

Authors:  Cyril Fersing; Nicolas Masurier; Léa Rubira; Emmanuel Deshayes; Vincent Lisowski
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-16

6.  From Automated Synthesis to In Vivo Application in Multiple Types of Cancer-Clinical Results with [68Ga]Ga-DATA5m.SA.FAPi.

Authors:  Lukas Greifenstein; Carsten S Kramer; Euy Sung Moon; Frank Rösch; Andre Klega; Christian Landvogt; Corinna Müller; Richard P Baum
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-14

7.  In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA5.SA.FAPi and DOTA.SA.FAPi.

Authors:  Euy Sung Moon; Yentl Van Rymenant; Sandeep Battan; Joni De Loose; An Bracke; Pieter Van der Veken; Ingrid De Meester; Frank Rösch
Journal:  Molecules       Date:  2021-06-08       Impact factor: 4.411
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.